AstraZeneca wins U.S. nod for first fixed-duration all-oral CLL combo
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AstraZeneca ( (GB:AZN) ) has issued an update.
AstraZeneca has secured U.S. FDA approval for Calquence (acalabrutinib) in combination with venetoclax as the first all-oral, fixed-duration regimen for adults with previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma. The 14-month combination is intended to offer an effective, time-limited alternative to continuous treatment, giving physicians more flexibility to align therapy with patient needs.
The approval is backed by the Phase III AMPLIFY trial, where the Calquence plus venetoclax regimen showed a statistically significant progression-free survival benefit over standard chemoimmunotherapy, with 77% of patients progression-free at three years versus 67% on chemotherapy. Safety was consistent with the known Calquence profile, and the regimen, already cleared in Europe, Canada, the U.K. and other markets, is expected to strengthen AstraZeneca’s competitive position in first-line CLL and support its broader push to redefine care in B‑cell blood cancers.
AstraZeneca is also developing Calquence further as a single agent and in combinations across multiple B‑cell malignancies, including mantle cell lymphoma and diffuse large B‑cell lymphoma. The expanded label in the U.S., alongside ongoing global regulatory reviews, underscores the company’s strategy to build a leading haematology franchise and may increase uptake of its BTK inhibitor-based regimens in a large and growing CLL population.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £16781.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
The score is driven primarily by strong underlying financial performance and a constructive earnings outlook (growth guidance and pipeline progress). This is tempered by valuation (P/E ~30), recent free-cash-flow variability, and technical signals that appear overextended despite the broader uptrend.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines in oncology, rare diseases and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. Based in Cambridge, U.K., its medicines are sold in more than 125 countries, and the group has built a broad oncology and haematology portfolio supported by acquisitions such as Alexion and Gracell Biotechnologies.
Average Trading Volume: 2,384,331
Technical Sentiment Signal: Buy
Current Market Cap: £241B
Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.
